Azenta will provide proteomics technology profiling on up to
20,000 individuals.
BURLINGTON, Mass., July 22,
2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA)
today announced its participation in the FinnGen project, a
large-scale research initiative at the forefront of personalized
medicine in Finland. The FinnGen
project is a pioneering endeavor that has collected and is
currently analyzing genomic and health data from a cohort of
500,000 Finnish biobank participants.
In collaboration with the University of
Helsinki, the organization leading the FinnGen study, Azenta
will provide comprehensive proteomics profiling on up to 20,000
individuals, underscoring Azenta's commitment to advancing
healthcare innovation and personalized treatments. Azenta will use
Olink's advanced proteomics technology, based on the proprietary
Proximity Extension Assay, to provide high-quality protein-level
measurements across all major biological pathways.
"FinnGen's adoption of proteomics marks a pivotal advancement in
our quest to decode the complexities of human health and disease.
By integrating the dynamic insights of proteomics with our
extensive genomic data, we can gain a deeper understanding of
disease mechanisms, identify new biomarkers for early detection,
and uncover novel therapeutic targets. We are pleased to
collaborate with Azenta Life Sciences, and trust that they will
provide excellent service and deliver high-quality proteomic data
with a fast turnaround time," said Professor Aarno
Palotie, FinnGen Scientific Director from the
Institute for Molecular Medicine Finland (FIMM), University of
Helsinki. "Combined with excellent quality and reliable
results, Azenta Life Sciences can help us construct a strong
foundation for advancing the field of personalized medicine."
"As one of the collaborators in the FinnGen Project, Azenta
looks forward to making meaningful contributions to personalized
medicine and revolutionizing healthcare for generations to come,"
said Ginger Zhou, PhD., Senior Vice
President and General Manager, GENEWIZ Multiomics & Synthesis
Solutions from Azenta Life Sciences. "Multiomics technologies from
Azenta enable researchers to efficiently generate detailed
proteomics data from study participants carrying medically and
clinically significant genetic variants, opening up a world of
possibilities for understanding disease mechanisms and developing
targeted treatments."
About FinnGen
FinnGen is a large public-private partnership aiming to collect
and analyze genome and health data from 500,000 Finnish biobank
participants. FinnGen aims on one hand to provide novel medically
and therapeutically relevant insights but also construct a
world-class resource that can be applied for future studies.
FinnGen is one of the very first personalized medicine projects
at this scale and the public-private collaborative nature of the
project is exceptional compared to many ongoing studies. FinnGen
brings together Finnish universities, hospitals and hospital
districts, THL, Blood Service, biobanks, FINBB and international
pharmaceutical companies and hundreds of thousands of Finns.
Because collaboration is the key to achieving breakthroughs in
disease prevention, diagnosis, and treatment, we welcome everyone
on this journey into our shared heritage.
For more information, please visit
https://www.finngen.fi/en.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research,
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic, and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington, Massachusetts, with operations in North
America, Europe and Asia. For more information,
please visit www.azenta.com.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are forward-looking statements
made under Section 21E of the Securities Exchange Act of 1934.
These statements are neither promises nor guarantees but involve
risks and uncertainties, both known and unknown, that could cause
Azenta's financial and business results to differ materially from
our expectations. They are based on the facts known to management
at the time they are made. Other forward-looking statements include
but are not limited to statements about the prospects of the
FinnGen Project and our ability to contribute to the advancement of
personalized medicine. Factors that could cause results to differ
from our expectations include the following: changes in technology
and/or science that impact our ability to enable researchers to
generate the proteomics data required to understand disease and
develop targeted treatments and other factors and other risks,
including those that we have described in our filings with the
Securities and Exchange Commission, including but not limited to
our Annual Report on Form 10-K, Current Reports on Form 8-K and our
Quarterly Reports on Form 10-Q. As a result, we can provide no
assurance that our future results will not be materially different
from those projected. Azenta expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statement to reflect any change in our expectations or any
change in events, conditions, or circumstances on which any such
statement is based. Azenta undertakes no obligation to update the
information contained in this press release.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor
Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
Azenta's use of third-party trademarks and brands are for
identification only and does not imply affiliation or
endorsement. All trademarks used herein are the property of
their respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/finngen-selects-azenta-to-propel-personalized-medicine-for-population-health-study-302203113.html
SOURCE Azenta